Abstract
Our coverage of emerging findings in psychopharmacology is generally limited to what gets published in the refereed scientific literature. Occasionally, however, something appears in the lay media that we think Update readers will benefit from knowing about. A recent such “something” was an article published in the New York Times under the alarming title “The F.D.A. [Food and Drug Administration] Warned an Asthma Drug Could Induce Despair. Many Were Never Told” (Jewett & Mueller, 2024). Broad coverage of this by other media outlets ensued.
Reference10 articles.
1. Apata J. Lyons J.G. Bradley M.C. et al. (2023). Assessing the risk of intentional self‐harm in montelukast users: An updated Sentinel System analysis using ICD‐10 coding.J Asthma.https://doi.org/10.1080/02770903.2023.2293064.
2. Ekhart C. van Hunsel F. Sellick V. et al. (2022). Neuropsychiatric reactions with the use of montelukast.BMJ.https://doi.org/10.1136/bmj‐2021‐067554.
3. Food and Drug Administration. (2020 March 4).FDA requires stronger warning about risk of neuropsychiatric events associated with asthma and allergy medication Singulair and generic montelukast.https://www.fda.gov/news‐events/press‐announcements/fda‐requires‐stronger‐warning‐about‐risk‐neuropsychiatric‐events‐associated‐asthma‐and‐allergy.
4. Haarman M.G. van Hunsel F. DeVries T.W.(2017). Adverse drug reactions of montelukast in children and adults.Pharmacol Res Perspect.https://doi.org/10.1002/prp2.341.
5. Jewett C.&Mueller B.(2024 Jan 9).The F.D.A. warned an asthma drug could induce despair. Many were never told.https://www.nytimes.com/2024/01/09/health/fda‐singulair‐asthma‐drug‐warning‐html.